Accounting for All Patients in Waterfall Plots.
作者信息
Moon James, LeBlanc Michael, Othus Megan
机构信息
Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.
出版信息
JCO Clin Cancer Inform. 2021 Apr;5:414-420. doi: 10.1200/CCI.20.00150.
Abstract
摘要
相似文献
1
Accounting for All Patients in Waterfall Plots.瀑布图中所有患者的统计分析。
JCO Clin Cancer Inform. 2021 Apr;5:414-420. doi: 10.1200/CCI.20.00150.
2
Use and misuse of waterfall plots.瀑布图的使用和误用。
J Natl Cancer Inst. 2014 Oct 29;106(12). doi: 10.1093/jnci/dju331. Print 2014 Dec.
3
Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals.评估医学期刊中癌症治疗反应率瀑布图表示的准确性。
JAMA Netw Open. 2019 May 3;2(5):e193981. doi: 10.1001/jamanetworkopen.2019.3981.
4
Two-dimensional correlation analysis and waterfall plots for detecting positional fluctuations of spectral changes.二维相关分析和瀑布图用于检测光谱变化的位置波动。
Appl Spectrosc. 2011 Apr;65(4):359-68. doi: 10.1366/10-06114.
5
Data augmentation based on waterfall plots to increase value of response data generated by small single arm Phase II trials.基于瀑布图的数据增强方法，提高小样本单臂 II 期临床试验应答数据的价值。
Contemp Clin Trials. 2021 Nov;110:106589. doi: 10.1016/j.cct.2021.106589. Epub 2021 Oct 9.
6
From waterfall plots to spaghetti plots in early oncology clinical development.从瀑布图到早期肿瘤学临床开发中的意大利面条图。
Pharm Stat. 2019 Oct;18(5):526-532. doi: 10.1002/pst.1944. Epub 2019 Apr 3.
7
Arterial and venous coronary pressure-flow relations in anesthetized dogs. Evidence for a vascular waterfall in epicardial coronary veins.麻醉犬的冠状动脉动静脉压力-流量关系。心外膜冠状静脉存在血管瀑布现象的证据。
Circ Res. 1984 Aug;55(2):238-48. doi: 10.1161/01.res.55.2.238.
8
The β-Blocker Esmolol Restores the Vascular Waterfall Phenomenon After Acute Endotoxemia.β受体阻滞剂艾司洛尔可恢复急性内毒素血症后的血管瀑布现象。
Crit Care Med. 2017 Dec;45(12):e1247-e1253. doi: 10.1097/CCM.0000000000002721.
9
Understanding waterfall plots.理解瀑布图。
J Adv Pract Oncol. 2012 Mar;3(2):106-11.
10
Disintegration of the 'waterfall phenomenon' in the inferior vena cava due to right heart failure.右心衰竭导致下腔静脉“瀑布现象”消失。
Respirology. 1996 Mar;1(1):5-9. doi: 10.1111/j.1440-1843.1996.tb00005.x.
引用本文的文献
1
A bootstrapping method to optimize go/no-go decisions from single-arm, signal-finding studies in oncology.一种自举法，用于优化肿瘤学中单臂、信号发现研究中的是/否决策。
CPT Pharmacometrics Syst Pharmacol. 2024 Aug;13(8):1317-1326. doi: 10.1002/psp4.13161. Epub 2024 Jun 11.
2
Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.NCI-MATCH 试验中精准药物的肿瘤特异性活性。
Clin Cancer Res. 2024 Feb 16;30(4):786-792. doi: 10.1158/1078-0432.CCR-23-0983.
本文引用的文献
1
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.在非胰腺神经内分泌肿瘤患者中进行的双重抗 CTLA-4 和抗 PD-1 阻断的罕见肿瘤 II 期篮子试验（DART SWOG 1609）。
Clin Cancer Res. 2020 May 15;26(10):2290-2296. doi: 10.1158/1078-0432.CCR-19-3356. Epub 2020 Jan 22.
2
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials.厄洛替尼/贝伐珠单抗治疗晚期细支气管肺泡癌或从不吸烟的晚期非小细胞肺癌的 II 期配对研究：SWOG S0635 和 S0636 试验。
Clin Lung Cancer. 2018 Jan;19(1):84-92. doi: 10.1016/j.cllc.2017.06.016. Epub 2017 Jul 6.
3
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.纳武利尤单抗治疗 BRAF V600 突变型和野生型晚期黑色素瘤患者的疗效和安全性：四项临床试验的汇总分析。
JAMA Oncol. 2015 Jul;1(4):433-40. doi: 10.1001/jamaoncol.2015.1184.
4
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.克唑替尼治疗晚期肺腺癌伴 ROS1 重排：EUROS1 队列研究结果。
J Clin Oncol. 2015 Mar 20;33(9):992-9. doi: 10.1200/JCO.2014.58.3302. Epub 2015 Feb 9.
5
Use and misuse of waterfall plots.瀑布图的使用和误用。
J Natl Cancer Inst. 2014 Oct 29;106(12). doi: 10.1093/jnci/dju331. Print 2014 Dec.
6
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.MEK162 治疗携带 NRAS 或 Val600 BRAF 突变的晚期黑色素瘤患者：一项非随机、开放标签的 2 期研究。
Lancet Oncol. 2013 Mar;14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X. Epub 2013 Feb 13.
7
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.索拉非尼联合卡铂和紫杉醇治疗转移性葡萄膜黑素瘤的 II 期临床试验：SWOG S0512。
PLoS One. 2012;7(11):e48787. doi: 10.1371/journal.pone.0048787. Epub 2012 Nov 30.
8
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).未经治疗的转移性黑色素瘤中索拉非尼联合替西罗莫司或替匹法尼的随机 II 期试验（S0438）。
Clin Cancer Res. 2012 Feb 15;18(4):1129-37. doi: 10.1158/1078-0432.CCR-11-2488. Epub 2012 Jan 6.
9
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.索拉非尼用于转移性肾细胞癌患者的II期安慰剂对照随机停药试验。
J Clin Oncol. 2006 Jun 1;24(16):2505-12. doi: 10.1200/JCO.2005.03.6723. Epub 2006 Apr 24.
Zotero 插件